该产品的成功获批是公司持续重视研发创新、不断丰富产品管线的体现，并且进一步丰富了公司猪用疫 苗产品矩阵，经过多年积累，公司已在猪用疫苗领域拥有丰富的产品储备，可满足市场多样化需求，并 为下游养殖客户提供多维度综合防疫解决方案，巩固公司在动物疫苗领域的行业地位，对提升公司研发 能力、市场竞争力和可持续发展等方面具有积极的促进作用。 智通财经APP讯，生物股份(600201.SH)发布公告，根据国家《兽药管理条例》和《兽药注册办法》规 定，经国家农业农村部审查，批准公司全资子公司扬州优邦生物药品有限公司(以下简称"扬州优邦")、 金宇保灵生物药品有限公司(以下简称"金宇保灵")和其他公司共同研制的猪细小病毒杆状病毒载体灭活 疫苗(rPP03株)为新兽药。 ...

Core Viewpoint - The approval of the inactivated vaccine for porcine parvovirus by the Ministry of Agriculture and Rural Affairs represents a significant achievement for the company, highlighting its commitment to research and development innovation in the animal vaccine sector [1] Group 1: Product Development - The newly approved vaccine, developed by the company's subsidiary Yangzhou Youbang Biological Pharmaceutical Co., Ltd. and Jin Yu Bao Ling Biological Pharmaceutical Co., Ltd., is classified as a new veterinary drug [1] - This product enhances the company's portfolio of swine vaccines, reflecting years of accumulated expertise in the field [1] Group 2: Market Position and Strategy - The successful approval of the vaccine strengthens the company's position in the animal vaccine industry and supports its ability to provide comprehensive disease prevention solutions to livestock customers [1] - The company aims to meet diverse market demands through its extensive product offerings, which contribute positively to its research capabilities, market competitiveness, and sustainable development [1]